Program
nucresiran
Also written as “Nucresiran” and “ALN-TTRSC04”.
Its studies are mostly in Cardiomyopathies · Polyneuropathies · Amyloidosis, led by Alnylam Pharmaceuticals.
Furthest: phase 3, since Jun 30, 20253 company-led studies, 2 open or runningNext primary completion: Dec 27, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alnylam Pharmaceuticals | 32 open or running | phase 3since Jun 30, 2025 | Dec 15, 2022 | Dec 27, 2027phase 3 · NCT07223203 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 15, 2022First study: phase 1 study in Transthyretin-Mediated AmyloidosisFirst studyNCT05661916 · 96 enrolled · United Kingdom
- Jun 30, 2025Phase 3 study in CardiomyopathiesNCT07052903 · 1,750 planned · United States, Argentina, Australia and more
- Oct 29, 2025Phase 3 study in PolyneuropathiesNCT07223203 · 125 planned · United States, Argentina, Australia and more
Ahead
- Dec 27, 2027Primary completion: phase 3 study in PolyneuropathiesNCT07223203
- May 28, 2030Primary completion: phase 3 study in CardiomyopathiesNCT07052903
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07223203Polyneuropathies · United States, Argentina, Australia and more | 3 | Recruiting | Dec 27, 2027 | 125 |
| NCT07052903Cardiomyopathies · United States, Argentina, Australia and more | 3 | Recruiting | May 28, 2030 | 1,750 |
| NCT05661916Transthyretin-Mediated Amyloidosis · United Kingdom | 1 | Completed | Sep 30, 2025 | 96 |
How it is read
Names in the registry
- “Nucresiran”, 2 entries
- “ALN-TTRSC04”, 1 entry
Conditions, from the studies’ own filings
- Cardiomyopathies, 1 study
- Polyneuropathies, 1 study
- Amyloidosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.